AI-Designed Vaccine Antigen Clears First Human Safety Trial

Researchers at the University of Cambridge and biotech company DIOSynVax reported that an AI-designed coronavirus vaccine antigen was safe and well tolerated in 39 adults, but protection remains unproven.